10x Genomics, Inc.
Price Action
Technical Summary
STAGE 2 UPTREND10x Genomics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 64% provides fundamental context to the price action. However, price is extended 44% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $33.71 | +18.67% | ABOVE |
| 50 SMA | $27.80 | +43.88% | ABOVE |
| 100 SMA | $24.36 | +64.22% | ABOVE |
| 150 SMA | $22.46 | +78.09% | ABOVE |
| 200 SMA | $20.26 | +97.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TXG in an uptrend right now?
TXG has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, TXG is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is TXG overbought or oversold?
TXG's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is TXG outperforming the market?
TXG has a Relative Strength (RS) Rating of 97 out of 99. Yes, TXG is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is TXG in its 52-week range?
TXG is trading at $40.00, which is 99% of its 52-week high ($40.56) and 98% above its 52-week low ($11.16).
How volatile is TXG?
TXG has a Beta of 2.24 and 52-week volatility of 69%. It's more volatile than the S&P 500 - expect bigger swings.